IBDEI15X ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20795,1,8,0)
 ;;=8^Thrombocytopenia Nos
 ;;^UTILITY(U,$J,358.3,20795,2)
 ;;=^118988
 ;;^UTILITY(U,$J,358.3,20796,0)
 ;;=287.30^^118^1254^21
 ;;^UTILITY(U,$J,358.3,20796,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20796,1,1,0)
 ;;=1^287.30
 ;;^UTILITY(U,$J,358.3,20796,1,8,0)
 ;;=8^Primary Thrombocytopenia (ITP)
 ;;^UTILITY(U,$J,358.3,20796,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,20797,0)
 ;;=238.71^^118^1254^24
 ;;^UTILITY(U,$J,358.3,20797,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20797,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,20797,1,8,0)
 ;;=8^Thrombocytosis,Essential
 ;;^UTILITY(U,$J,358.3,20797,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,20798,0)
 ;;=286.53^^118^1254^4
 ;;^UTILITY(U,$J,358.3,20798,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20798,1,1,0)
 ;;=1^286.53
 ;;^UTILITY(U,$J,358.3,20798,1,8,0)
 ;;=8^Antiphospholipid w/ Hemor d/o
 ;;^UTILITY(U,$J,358.3,20798,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,20799,0)
 ;;=286.0^^118^1254^7
 ;;^UTILITY(U,$J,358.3,20799,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20799,1,1,0)
 ;;=1^286.0
 ;;^UTILITY(U,$J,358.3,20799,1,8,0)
 ;;=8^Congenital Factor VII Disorder
 ;;^UTILITY(U,$J,358.3,20799,2)
 ;;=^27454
 ;;^UTILITY(U,$J,358.3,20800,0)
 ;;=286.1^^118^1254^5
 ;;^UTILITY(U,$J,358.3,20800,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20800,1,1,0)
 ;;=1^286.1
 ;;^UTILITY(U,$J,358.3,20800,1,8,0)
 ;;=8^Cogenital Factor IX Disorder
 ;;^UTILITY(U,$J,358.3,20800,2)
 ;;=^27452
 ;;^UTILITY(U,$J,358.3,20801,0)
 ;;=286.2^^118^1254^8
 ;;^UTILITY(U,$J,358.3,20801,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20801,1,1,0)
 ;;=1^286.2
 ;;^UTILITY(U,$J,358.3,20801,1,8,0)
 ;;=8^Congenital Factor XI Deficiency
 ;;^UTILITY(U,$J,358.3,20801,2)
 ;;=^27456
 ;;^UTILITY(U,$J,358.3,20802,0)
 ;;=286.3^^118^1254^6
 ;;^UTILITY(U,$J,358.3,20802,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20802,1,1,0)
 ;;=1^286.3
 ;;^UTILITY(U,$J,358.3,20802,1,8,0)
 ;;=8^Congenital Def of Oth Clotting
 ;;^UTILITY(U,$J,358.3,20802,2)
 ;;=^27437
 ;;^UTILITY(U,$J,358.3,20803,0)
 ;;=286.4^^118^1254^28
 ;;^UTILITY(U,$J,358.3,20803,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20803,1,1,0)
 ;;=1^286.4
 ;;^UTILITY(U,$J,358.3,20803,1,8,0)
 ;;=8^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,20803,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,20804,0)
 ;;=286.52^^118^1254^2
 ;;^UTILITY(U,$J,358.3,20804,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20804,1,1,0)
 ;;=1^286.52
 ;;^UTILITY(U,$J,358.3,20804,1,8,0)
 ;;=8^Acquired Hemophilia
 ;;^UTILITY(U,$J,358.3,20804,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,20805,0)
 ;;=286.59^^118^1254^16
 ;;^UTILITY(U,$J,358.3,20805,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20805,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,20805,1,8,0)
 ;;=8^Oth Hemor d/o d/t Anticoagulant
 ;;^UTILITY(U,$J,358.3,20805,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,20806,0)
 ;;=286.6^^118^1254^10
 ;;^UTILITY(U,$J,358.3,20806,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20806,1,1,0)
 ;;=1^286.6
 ;;^UTILITY(U,$J,358.3,20806,1,8,0)
 ;;=8^Defibrination Syndrome
 ;;^UTILITY(U,$J,358.3,20806,2)
 ;;=^35673
 ;;^UTILITY(U,$J,358.3,20807,0)
 ;;=286.7^^118^1254^1
 ;;^UTILITY(U,$J,358.3,20807,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20807,1,1,0)
 ;;=1^286.7
 ;;^UTILITY(U,$J,358.3,20807,1,8,0)
 ;;=8^Acquired Coagulation Factor Def
 ;;^UTILITY(U,$J,358.3,20807,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,20808,0)
 ;;=287.0^^118^1254^3
 ;;^UTILITY(U,$J,358.3,20808,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20808,1,1,0)
 ;;=1^287.0
 ;;^UTILITY(U,$J,358.3,20808,1,8,0)
 ;;=8^Allergic Purpura
 ;;^UTILITY(U,$J,358.3,20808,2)
 ;;=^101365
